Toxicology

Drug toxicity is a key reason for drug attrition. Identifying potential toxicity at an early stage in drug discovery can save both time and development costs, and reduce the likelihood of late stage failure.

Cyprotox assist you in understanding the toxic liability of your compounds using a panel of different techniques. We can help you identify which compounds have the optimal ADME and safety profile to advance into the clinic. Our focus on state of the art technology and automation allow high quality data to be generated rapidly and cost effectively.

Cyprotox have invested in a high content screening platform which uses automated fluorescence imaging to simultaneously analyse multi-parametric indicators of cytotoxicity. This improves the prediction of toxicological events and allows a better understanding of the mechanisms of drug toxicity. We also offer single point cell viability endpoints such as MTT, neutral red and LDH.

Cyprotox offer a number of other services including reactive metabolite detection using trapping agents, drug-induced phospholipidosis, hemolysis, mitochondrial toxicity assessment using cells grown in glucose and galactose media, hERG inhibition using automated patch clamp, toxicological gene regulation using qRT-PCR and a range of drug-drug interaction screens (available via Cyprotex ADME services). Cyprotox can also assess the potential genotoxicity of your compound using GreenScreen HC™, Ames Test, in vitro Comet or the in vitro micronucleus test.

Toxicology Services